NDAORALTABLETPriority Review
Approved
Aug 2019
Lifecycle
Post-LOE
Competitive Pressure
35/100
Clinical Trials
8
Data completeness
5/8 — Partial
Priority Review
PRETOMANID (pretomanid) by Viatris (2) is organic anion transporter 3 inhibitors [moa]. Approved for tuberculosis, multidrug-resistant, tuberculosis, extensively drug-resistant, pulmonary tuberculosis. First approved in 2019.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pretomanid is an oral antimycobacterial tablet approved in 2019 for treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, including rifampicin-resistant TB. It works as an organic anion transporter 3 inhibitor, a novel mechanism for TB treatment. The drug addresses a critical unmet need in difficult-to-treat TB populations where standard regimens have failed.
$0.056MPart D
Post-LOEPost-LOEPretomanid has reached loss-of-exclusivity (August 2024) and shows minimal commercial uptake ($56K spending, 81 claims in 2023), signaling a niche specialty product with a small, highly focused brand team.
Mechanism of Action
Organic Anion Transporter 3 Inhibitors
Pharmacologic Class:
Antimycobacterial
Worked on PRETOMANID at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.